Vivoryon Therapeutics N.V.
VVY | AS
Overview
Corporate Details
- ISIN(s):
- NL00150002Q7
- LEI:
- 3912004AMB0KGZXZYJ15
- Country:
- Germany
- Address:
- Weinbergweg 22, 06120 Halle (Saale)
- Website:
- https://www.vivoryon.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
We are focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-11 07:44 |
Earnings Release
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational …
|
English | 650.9 KB | |
| 2025-06-06 10:30 |
Regulatory News Service
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND …
|
English | 654.5 KB | |
| 2025-06-05 14:00 |
Regulatory News Service
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Dis…
|
English | 8.8 KB | |
| 2025-05-27 07:44 |
Regulatory News Service
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S…
|
English | 686.4 KB | |
| 2025-04-29 07:02 |
Annual Report
Vivoryon Therapeutics N.V., Jaarlijkse financiële verslaggeving
|
English | 10.7 MB | |
| 2025-04-25 07:42 |
Inside Information Statement
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
|
English | 656.2 KB | |
| 2025-02-11 18:12 |
Regulatory News Service
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on Febr…
|
English | 629.7 KB | |
| 2024-12-10 07:49 |
Earnings Release
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on V…
|
English | 674.7 KB | |
| 2024-11-20 17:07 |
Earnings Release
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
|
English | 2.0 MB | |
| 2024-10-28 07:39 |
Earnings Release
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutam…
|
English | 722.2 KB | |
| 2024-10-11 16:18 |
Regulatory News Service
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the Ame…
|
English | 222.8 KB | |
| 2024-10-01 07:40 |
Regulatory News Service
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Ev…
|
English | 210.7 KB | |
| 2024-09-12 10:36 |
Earnings Release
Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney…
|
English | 803.6 KB | |
| 2024-09-12 07:05 |
Interim Report
|
English | 1.3 MB | |
| 2024-09-06 07:15 |
Inside Information Statement
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and …
|
English | 612.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-04-01 | E. Platzer | Executive member | Buy | 123,809 | 1,299,994.50 EUR |
| 2022-04-01 | U. Dauer | Executive member | Buy | 4,761 | 49,990.50 EUR |
| 2020-12-02 | D.J. von der Osten | Executive member | Buy | 20,000 | 112,400.00 EUR |
| 2020-11-30 | M. Schaeffer | Executive member | Other | 3,867 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |